---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-003117"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:39:21.978571+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "low"
source: SEC EDGAR
---

# Coherus Oncology provides preliminary FY2025 revenue and cash at J.P. Morgan conference

## Summary
- Filing furnishes preliminary unaudited net revenues for Q4 and FY2025 ended Dec 31, 2025.
- Preliminary cash, cash equivalents and investments as of Dec 31, 2025 also disclosed.
- Slide includes forward-looking projection of LOQTORZI revenue growth.
- Actual final results may differ materially; independent auditor has not reviewed these preliminary figures.

## SEC filing metadata
- accession: 0001104659-26-003117
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: low
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000110465926003117/0001104659-26-003117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000110465926003117/chrs-20260113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-003117
- JSON: https://secwatch.observer/filing/0001104659-26-003117.json
- Plain text: https://secwatch.observer/filing/0001104659-26-003117.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.